A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Phase 2 Enrolling by invitation 44 enrolled Vertex Pharmaceuticals Incorporated

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).

Timeline

Start: 2025-04-28
Primary completion: 2029-01-30
Completion: 2029-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-670	Unknown	—	Intravenous

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Summary

Timeline

Drugs

Indications